For the 7.2% of the cases tested by NGS without finding any of tier 1 and tier 2 mutations in neither EGFR nor non-EGFR genes, but we think tier 3 variants (variants of unknown clinical significance-VUS, not reported) found in these cases might represent potentially useful biomarkers for monitoring cancer treatment effects via liquid biopsy. Here, EGFR is linked to cancer.